Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.
Hideki KitaharaKazuya TateishiYuki ShikoYusuke InabaYoshio KobayashiTakahiro InouePublished in: PloS one (2022)
Combination of low-dose prasugrel and DOAC was associated with lower incidence of MI, ischemic stroke, and blood transfusion. Low-dose prasugrel may be feasible as part of triple therapy in patients undergoing PCI.
Keyphrases
- percutaneous coronary intervention
- low dose
- atrial fibrillation
- st segment elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- high dose
- patients undergoing
- direct oral anticoagulants
- coronary artery bypass
- risk factors
- venous thromboembolism
- heart failure
- mesenchymal stem cells